Similar results were found regarding influenza patients: none received tocilizumab or another anti-interleukine-6 or anti-interleukine-1; but among the 60 patients who had at least one Herpesviridae reactivation (HSV, CMV or both), 10 (17%) received corticosteroids, whereas among the 29 patients without any Herpesviridae reactivation, 3 (10%) received corticosteroids (p = 0.53 for between groups comparison). Here, IL6 is linked to influenza.